ID: ALA349204

Max Phase: Preclinical

Molecular Formula: C31H25N3O5

Molecular Weight: 519.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)Nc1ccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3c3ccc4c(c3)OCO4)o2)cc1

Standard InChI:  InChI=1S/C31H25N3O5/c1-18(35)32-21-9-6-19(7-10-21)25-12-13-27(39-25)31(36)34-15-14-23-22-4-2-3-5-24(22)33-29(23)30(34)20-8-11-26-28(16-20)38-17-37-26/h2-13,16,30,33H,14-15,17H2,1H3,(H,32,35)

Standard InChI Key:  CESZVDFKPQPIGI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 519.56

Molecular Weight (Monoisotopic): 519.1794

AlogP: 5.90

#Rotatable Bonds: 4

Polar Surface Area: 96.80

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 13.95

CX Basic pKa:

CX LogP: 4.33

CX LogD: 4.33

Aromatic Rings: 5

Heavy Atoms: 39

QED Weighted: 0.31

Np Likeness Score: -0.76

References

1. Sui Z, Guan J, Macielag MJ, Jiang W, Qiu Y, Kraft P, Bhattacharjee S, John TM, Craig E, Haynes-Johnson D, Clancy J..  (2003)  Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.,  13  (4): [PMID:12639576] [10.1016/s0960-894x(02)01036-3]

2. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature